[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503515":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":35,"responsibleParty":164,"collaborators":24,"id":166,"slug":167,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":168,"sex":174,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":24,"studyType":180,"phases":181,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},{"fullName":5,"class":6},"Tenaya Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Dose for Cohort 1 will be 3E13 vg\u002Fkg",[13],"Genetic: TN-201",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Dose for Cohort 2 will be 6E13 vg\u002Fkg",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"GENETIC","TN-201","TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Matt Pollman, M.D.","CONTACT","650-209-8092","mpollman@tenayathera.com",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"LaTanya Tomlinson, RN, MHSA","650-825-6990","clinical.trials@tenayathera.com",[36,55,69,80,90,105,115,129,139,149],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research","RECRUITING","La Jolla","California","92093","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-117.2742,32.84727,{"lat":48,"lon":47},[51],{"name":52,"role":28,"phone":53,"phoneExt":24,"email":54},"Matt Fahey","858-534-3798","mjfahey@health.ucsd.edu",{"facility":56,"status":38,"city":57,"state":40,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"University of California San Francisco","San Francisco","94117",{"type":45,"coordinates":60},[61,62],-122.41942,37.77493,{"lat":62,"lon":61},[65],{"name":66,"role":28,"phone":67,"phoneExt":24,"email":68},"Emma Reagan","415-514-7280","Emma.reagan@ucsf.edu",{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":42,"countryCode":43,"cosmosGeoPoint":75,"geoPoint":79,"contacts":24},"Emory University","WITHDRAWN","Atlanta","Georgia","30322",{"type":45,"coordinates":76},[77,78],-84.38798,33.749,{"lat":78,"lon":77},{"facility":81,"status":71,"city":82,"state":83,"zip":84,"country":42,"countryCode":43,"cosmosGeoPoint":85,"geoPoint":89,"contacts":24},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":45,"coordinates":86},[87,88],-71.05977,42.35843,{"lat":88,"lon":87},{"facility":91,"status":38,"city":92,"state":93,"zip":94,"country":42,"countryCode":43,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Mayo Clinic","Rochester","Minnesota","55905",{"type":45,"coordinates":96},[97,98],-92.4699,44.02163,{"lat":98,"lon":97},[101],{"name":102,"role":28,"phone":103,"phoneExt":24,"email":104},"Sierra Slade","507-422-5433","Slade.Sierra@mayo.edu",{"facility":106,"status":71,"city":107,"state":108,"zip":109,"country":42,"countryCode":43,"cosmosGeoPoint":110,"geoPoint":114,"contacts":24},"The Christ Hospital Physicians - The Ohio Heart and Vascular Center","Cincinnati","Ohio","45219",{"type":45,"coordinates":111},[112,113],-84.51439,39.12711,{"lat":113,"lon":112},{"facility":116,"status":38,"city":117,"state":108,"zip":118,"country":42,"countryCode":43,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Cleveland Clinic","Cleveland","44195",{"type":45,"coordinates":120},[121,122],-81.69541,41.4995,{"lat":122,"lon":121},[125],{"name":126,"role":28,"phone":127,"phoneExt":24,"email":128},"Rachael Landis","216-444-3650","LANDISR@ccf.org",{"facility":130,"status":71,"city":131,"state":132,"zip":133,"country":42,"countryCode":43,"cosmosGeoPoint":134,"geoPoint":138,"contacts":24},"Oregon Health & Science University","Portland","Oregon","97239",{"type":45,"coordinates":135},[136,137],-122.67621,45.52345,{"lat":137,"lon":136},{"facility":140,"status":71,"city":141,"state":142,"zip":143,"country":42,"countryCode":43,"cosmosGeoPoint":144,"geoPoint":148,"contacts":24},"Hospital of the University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":45,"coordinates":145},[146,147],-75.16362,39.95238,{"lat":147,"lon":146},{"facility":150,"status":38,"city":151,"state":152,"zip":153,"country":42,"countryCode":43,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Houston Methodist Hospital","Houston","Texas","77030",{"type":45,"coordinates":155},[156,157],-95.36327,29.76328,{"lat":157,"lon":156},[160],{"name":161,"role":28,"phone":162,"phoneExt":24,"email":163},"Jennifer Garrett","281-222-9983","jmgarrett@houstonmethodist.org",{"type":165,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100503515","phase-1-multi-center-open-label-single-ascending-dose-study-of-safety-and-tolerability-of-tn-201-in-adults-with-symptomatic-mybpc3-mutation-associated-hcm-100503515",false,"NCT05836259","Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM","First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)","MyPEAK-1","Inclusion Criteria:\n\n* MYBPC3 mutation\n* Hypertrophic Cardiomyopathy (obstructive and nonobstructive)\n* Left Ventricular Ejection Fraction ≥45%\n* NYHA Functional Class II or III symptoms\n* NT-proBNP ≥160pg\u002Fml\n\nExclusion Criteria:\n\n* High AAV9 neutralizing antibody titer","ALL","18 Years","75 Years",{"count":178,"type":179},30,"ESTIMATED","INTERVENTIONAL",[182,183],"PHASE1","PHASE2","This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.",[186],"Hypertrophic Cardiomyopathy",[188,189,190,191,192,193,194,195,196,197],"Hypertrophic Cardiomyopathy (HCM)","Myosin Binding Protein C3 (MYBPC3)","Nonobstructive HCM","Genetic HCM","Familial HCM","Adenoassociated Virus (AAV)","Gene Therapy","Obstructive HCM","nHCM","oHCM","2026-03-18",{"date":200,"type":201},"2026-03-19","ACTUAL",{"date":203,"type":201},"2023-08-10",{"date":205,"type":179},"2032-08",{"name":5,"class":6},10]